International Gynecologic Cancer Society (IGCS) 2021 Annual Global Meeting

The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.

Intensive follow-up for 5 years did not improve overall survival (OS) or relapse-free survival (RFS) in patients who have undergone surgical treatment for endometrial cancer, according to results of the TOTEM study presented at IGCS 2021.

Cemiplimab appears to extend overall survival (OS) compared with investigator’s choice (IC) of chemotherapy in patients with recurrent or metastatic (R/M) cervical cancer who have progressed on first-line platinum-based chemotherapy, results of the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial showed.